O-glycnacylation Modifier for Vascular Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for critical limb ischemia (CLI) are inadequate, as they fail to induce sufficient functional blood vessel growth, leading to a significant clinical need for effective vascular regeneration methods.
Innovation Solution
Administering an effective amount of an O-glycnacylation modifier agent, optionally combined with an inflammation agent inducer or an angiogenic factor, to injured peripheral vascular tissue to promote vascular regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional treatments are used for critical limb ischemia, then current standard of care is maintained, but sufficient functional blood vessel growth is not induced
Solution Approach 1:
The patent applies parameter changes by modifying the metabolic state of fibroblasts through O-glycnacylation modification, which alters the cellular biochemical parameters to enable transdifferentiation into endothelial cells. This metabolic reprogramming changes the cell fate decision parameters, allowing fibroblasts to transform into functional endothelial cells that promote blood vessel growth in ischemic tissues.
Solution Approach 2:
The patent uses O-glycnacylation modification as an intermediary mechanism to facilitate the transdifferentiation process. The O-glycnacylation modifier acts as a mediator that bridges the gap between conventional fibroblast function and endothelial cell generation, enabling controlled cell fate transition without direct genetic manipulation or complex viral vectors.
2Object-affected harmful factors
If amputation is performed as treatment for critical limb ischemia, then severe ischemia is managed, but loss of limb function occurs
Solution Approach 1:
The patent converts the harmful ischemic condition into a beneficial therapeutic opportunity by exploiting the body's natural response to ischemia. The ischemic environment normally triggers maladaptive responses, but the patent redirects this signaling to promote fibroblast transdifferentiation into endothelial cells, thereby converting the harmful ischemic stimulus into a beneficial regenerative process that restores blood flow and saves the limb.
3Productivity
If fibroblasts are transdifferentiated to endothelial cells, then vascular regeneration is promoted, but sufficient functional blood vessel growth is still not achieved with current methods
Solution Approach 1:
The patent replaces complex mechanical and genetic manipulation systems with a biochemical approach. Instead of using viral vectors, transcription factors, or complex culture conditions to induce transdifferentiation, the patent employs O-glycnacylation modification—a biochemical post-translational modification—to naturally guide fibroblast differentiation into endothelial cells, thereby simplifying the system while improving functional outcomes.
Data Source
AI summary
Described are methods for vascular regeneration m a subject with peripheral vascular disease. Described are also methods of treating a wound. The methods can include administering an effective amount of an O-glycnacylation modifier agent described here. The method increases O-glycnacylation level in the wound compared to O-glycnacylation level without administration of an effective amount of an O-glycnacylation modifier agent.